



News Release

July 11, 2017
Maruho Co., Ltd.

Maruho Launches Topical Scalp Psoriasis Treatment “Comclo[®] Shampoo 0.05%” in Japan

Osaka (Japan), July 11, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces today that it has launched topical scalp psoriasis treatment “Comclo[®] Shampoo 0.05%” (INN: clobetasol propionate) (hereinafter referred to as “the product”) in Japan.

The product is a shampoo-like topical liquid formulation developed by Galderma Pharma S.A. (“Galderma SA”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman). Since its first marketing authorization in the US in 2004 for the treatment of scalp psoriasis vulgaris in adults, the product has been marketed in 62 countries around the world under the brand names Clobex Shampoo (US, etc.) and Etrivex Shampoo (UK, etc.) (As of June, 2017). With this launch, the product will be marketed in 63 countries around the world including Japan. Maruho and Galderma SA agreed on a license agreement focused on the development and commercialization of the product in Japan, and Maruho has been progressing its development.

Psoriasis vulgaris is a chronic skin disease characterized by redness/irritation and silvery-white scaling of the surface of the skin adhering to sites such as the head, hair line, waist and buttocks. The product is the first prescription shampoo topical formulation approved in Japan that can be applied once a day to the head and rinsed 15 minutes later (short contact therapy). Maruho hopes to increase the treatment options for psoriasis vulgaris of the scalp and contribute to increased medical adherence.

Maruho is confident that the product will contribute to the treatment of patients with psoriasis vulgaris of the scalp.



Product Profile: Comclo® Shampoo 0.05%

| | |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| INN | Clobetasol propionate |
| Formulation/Dose | Topical liquid containing 0.5mg per 1 gram of clobetasol propionate |
| Indication | Psoriasis vulgaris of the scalp |
| Dosage and Administration | General administration is to apply once daily to the head when dry, then after 15 minutes lather with hot or cold water and rinse off. |
| Packaging | Bottle: 125mL (125g) |
| NHI Drug Price Standard | 1g(1mL) 28.20yen |
| Date of Approval | March 30, 2017 |
| Date of NHI Price Listing | May 24, 2017 |
| Date of Launch | July 11, 2017 |
| Manufacturer | Maruho Co., Ltd. |

About Galderma

Galderma, Nestlé Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit www.galderma.com

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,398 employees (as of the end of September 2016), and net sales were approximately 70.1 billion yen in its 2016 fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit www.maruho.co.jp/english

Contact Information:

Maruho Co., Ltd.

Corporate Communications Dept.

Roger Matthews

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-8679

Email: kouhou@mii.maruho.co.jp